The Ensign Group, Inc. (ENSG) fair value analysis
Nasdaq · Updated 2026-10-19
ENSG price how computed
Forward Fair Value verdict
Fairly valuedENSG is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $176.63
- Sector
- Healthcare
- 12-month range
- $147.13–$215.83
- Market cap
- $10.3B
- From 52-week high
- -18.2%
- Shares outstanding
- 58.3M
- Rank in Healthcare by discount to fair value
- #44 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
The Ensign Group, Inc. operates skilled nursing facilities, assisted living communities, and other healthcare services across multiple states in the United States. The company provides post-acute care and senior living services to patients and residents in its facilities.
ENSG currently ranks #44 of 108 Healthcare stocks by discount to fair value. Its Fairly valued verdict is new as of this week's run.
Fundamentals (4 quarters) how computed
- Market cap
- $10.3B
- P/E (trailing)
- 25x
- Revenue (TTM)
- $5.49B
- Net margin
- 6.9%
- EPS (TTM)
- $7.03
- Gross margin
- 16.6%
- Debt / equity
- 0.92
- Revenue growth (3-yr avg)
- 17.7%
- Shares outstanding
- 58.3M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The lower-middle quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 55 · neutral
- 50-day average
- $175.67
- 200-day average
- $181.59
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $0.26 per share (4 payments)
- Yield on last price
- 0.15%
- Consecutive years of increases
- 9
- Last ex-dividend date
- 2026-09-30
- Last payment date
- 2026-10-31
Earnings how computed
- Next earnings report
- 2026-11-02
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.5%)
2026-03 ▲ beat (+1.6%)
2025-12 ▲ beat (+2.8%)
2025-09 ▲ beat (+1.9%)
2025-06 ▲ beat (+2.6%)
2025-03 ▼ miss (-8.1%)
2024-12 ▲ beat (+0.7%)
2024-09 ▲ beat (+0.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 4 buy · 1 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $220
- Target vs last price
- +24.6%
What our data shows for ENSG
- Our model validated 17 trailing price-to-earnings windows for ENSG, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $147.13–$215.83.
- The 14-day relative strength index sits at a neutral 55.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for ENSG
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent ENSG news
TickrTrends' derived news-sentiment signal for ENSG is currently leaning positive, computed from recent coverage.
- The Ensign Group Schedules Third Quarter 2026 Earnings Call for Wednesday, October 28, 2026 (manilatimes.net, 2026-10-23)
TickrTrends take: Ensign Group has scheduled its third quarter 2026 earnings call for October 28, 2026, providing an upcoming opportunity for investors to assess operational performance against current market expectations. Given TickrTrends' fairly valued assessment of ENSG, the earnings report will be a key moment to evaluate whether the Healthcare sector company's results justify its current valuation or signal potential shifts in its fundamental value. Valuation-focused investors should monitor revenue trends, margin performance, and management guidance during this call to determine if the fairly valued rating remains appropriate. - ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages The Ensign Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ENSG (markets.businessinsider.com, 2026-10-16)
TickrTrends take: Rosen Law Firm has encouraged Ensign Group investors to seek legal counsel regarding an ongoing securities class action, which introduces litigation risk that may not be fully reflected in current market pricing. For investors evaluating ENSG under TickrTrends' undervalued designation, the resolution timeline and potential financial impact of this legal matter represent material factors that could influence the company's future earnings and cash flow. The Healthcare sector context means investors should monitor how this litigation develops relative to ENSG's operational performance and balance sheet strength. - Ensign Group (ENSG) Expands Washington State Presence with Acquisition of Four Skilled Nursing Facilities (gurufocus.com, 2026-10-02)
TickrTrends take: Ensign Group's acquisition of four skilled nursing facilities in Washington State represents a geographic expansion strategy that increases its operational footprint in a new market. TickrTrends currently rates ENSG as undervalued within the Healthcare sector, suggesting the market may not have fully priced in the growth potential from such expansion activities. Investors focused on valuation should monitor whether this acquisition translates into revenue growth and margin improvements that justify the company's current market valuation.
More ENSG news
- The Ensign Group Announces Expansion Into Florida (manilatimes.net, 2026-10-02)
- The Ensign Group Adds Operations in Washington (manilatimes.net, 2026-10-02)
What people are saying
Follow the ENSG conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for ENSG showed mixed movements this week within the Healthcare sector. The 50/200-day trend state shifted from downtrend to mixed, while the sector discount rank declined from 50th to 55th position. The valuation verdict changed from Undervalued to Fairly valued.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is ENSG stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), ENSG is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is ENSG's TickrTrends verdict?
ENSG's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does ENSG compare to other Healthcare stocks?
ENSG ranks #44 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is ENSG overbought or oversold?
ENSG's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ENSG pay a dividend?
Yes. ENSG paid $0.26 per share over the last twelve months (4 payments), a 0.15% yield on TickrTrends' last price, and has raised the annual total for 9 consecutive years. The last ex-dividend date was 2026-09-30.
When does ENSG report earnings next?
ENSG's next earnings report is scheduled for 2026-11-02, per the published earnings calendar.
Does ENSG usually beat earnings estimates?
Over its last 8 reported quarters ENSG beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ENSG?
Of 5 analysts covering ENSG, 4 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $220 (+24.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
ENSG vs BAX · ENSG vs BBIO · ENSG vs EXEL · ENSG vs HSIC · ENSG vs INSM